Fennec Pharmaceuticals posted Q1 2026 adjusted EPS of $0.01, beating consensus estimate of -$0.04 by $0.05.
Revenue rose 73% YoY to $15.11 million, surpassing the $14.65 million forecast, driven by PEDMARK sales expansion.
Selling & marketing expenses jumped to $11.4 million from $3.2 million, while G&A fell to $3.2 million from $5.9 million.
Cash balances increased to $40.1 million as of March 31 2026, and the company expects this to fund operations under its current plan.